Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?

Older patients with acute myeloid leukemia (AML) face a dismal prognosis. Although venetoclax-based therapy has led to improved outcomes among unfit older patients with AML, it is not curative and its efficacy and long-term outcomes among fit older patients is unclear. This review provides insights...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical haematology 2021-12, Vol.34 (4), p.101335-101335, Article 101335
Main Author: Foran, James M.
Format: Article
Language:English
Subjects:
7+3
Acute myeloid leukemia
Aged
AML
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Azacytidine
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Complete remission
Humans
Intensive chemotherapy
Leukemia, Myeloid, Acute - drug therapy
Overall survival
Sulfonamides - therapeutic use
Venetoclax
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Older patients with acute myeloid leukemia (AML) face a dismal prognosis. Although venetoclax-based therapy has led to improved outcomes among unfit older patients with AML, it is not curative and its efficacy and long-term outcomes among fit older patients is unclear. This review provides insights into factors that influence treatment choices among older patients with AML and what we would need to know for venetoclax-based therapy to replace standard intensive 7 + 3 induction therapy.
ISSN:1521-6926
1532-1924
DOI:10.1016/j.beha.2021.101335